Blockchain Registration Transaction Record
NeuroOne Reports Q3 Revenue Growth, Backlog Up, StereoCED Launch Ahead
NeuroOne Q3 2026 results: revenue up 16%, gross margins at 59.9%, $11.2M orders, StereoCED launch, ISO certification, and collaborations with Mayo Clinic and University of Minnesota.
This news matters because NeuroOne's advancements in drug delivery and ablation technologies could transform treatments for neurological disorders like epilepsy and brain cancer, potentially improving patient outcomes and expanding market opportunities. The company's revenue growth and expanding margins signal financial health, while its strategic collaborations and international certification position it for broader commercial success, making it a key player to watch in the medtech space.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x38d93afe877eecf866a0e1233326610e78fff5dbaf8de891c6054c8a6566f192 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | noonkoAM-43a66bb1cfc944242bbde2c02eb8826c |